BioInvent International AB

BINV · Nasdaq Stockholm

Share price · BINV

$43.93+1.49 (+3.51%) 3M

no price since 25 Sep 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BINV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

No unusual moves in the past 12 months.

Share of unusual movement by asset

For each asset, the share of BINV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
BI-1910
events and moves
7shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—75%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
TNFR2Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
July 2027 (1)
BI-1910Phase 1/2Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
Est. primary completion 2027-07-14 · NCT06205706 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.

Insider transactions

Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.